What do systematic reviews say?

Corticosteroids vs placebo

Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 4.58 [1.66, 12.62]
  3 studies · 280 participants
  Moderate

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2.1 [0.21, 21.39]
  1 study · 41 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.37, 3.77]
  1 study · 39 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 269 participants
  Moderate

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.63 [0.12, 3.38]
  1 study · 39 participants
  Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2.14 [0.79, 5.79]
  1 study · 39 participants
  Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found